Perspective Therapeutics, Inc. (CATX)
$
2.4
+0.01 (0.42%)
Key metrics
Financial statements
Free cash flow per share
-1.5911
Market cap
178.4 Million
Price to sales ratio
309.6760
Debt to equity
0.0134
Current ratio
15.0899
Income quality
0.8755
Average inventory
0
ROE
-0.3887
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Perspective Therapeutics, Inc., along with its subsidiaries, specializes in the development, manufacturing, sale, and marketing of isotope-based medical products and devices aimed at treating cancer and other malignant diseases both domestically and internationally. The company achieved a revenue of $0.00 indicating its niche market focus. It reported a net loss of -$79,279,000.00 indicating challenges in its operations. The net income ratio is 0.00 reflecting the company's profitability margin. Furthermore, the company reported selling, general, and administrative expenses of $26,613,000.00 indicating its operational overhead costs. Additionally, Perspective Therapeutics incurred an interest expense of -$48,000.00 reflecting its debt servicing obligations. Formerly known as Isoray, Inc., the company changed its name to Perspective Therapeutics, Inc. in February 2022. Founded in 1998, it is located in Richland, Washington, and offers CS-1 Cesium-131 brachytherapy seeds for various cancers, serving facilities and physician practices that utilize different surgical environments. The stock is affordable at $3.19 suitable for budget-conscious investors. With a market capitalization of $178,373,359.00 the company is classified as a small-cap player. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth. Moreover, the stock has a high average trading volume of 1,500,693.00 indicating strong liquidity, which can be appealing to investors looking for opportunities in a dynamic market. This financial positioning, alongside its product offerings and industry standing, reflects Perspective Therapeutics' commitment to advancing cancer treatment solutions while navigating operational challenges.
Is Perspective Therapeutics, Inc. (CATX) a good investment?
Investing in Perspective Therapeutics, Inc. (CATX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Perspective Therapeutics, Inc. (CATX)'s stock forecast?
Analysts predict Perspective Therapeutics, Inc. stock to fluctuate between $1.60 (low) and $5.39 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Perspective Therapeutics, Inc.'s market capitalization?
As of 2025-12-05, Perspective Therapeutics, Inc.'s market cap is $178,373,359, based on 74,322,233 outstanding shares.
How does Perspective Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Perspective Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Perspective Therapeutics, Inc. (CATX) stock?
To buy Perspective Therapeutics, Inc. (CATX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CATX. Place an order (Market, Limit, etc.).
What is the best time to invest in Perspective Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Perspective Therapeutics, Inc. stock ever split?
Perspective Therapeutics, Inc.'s last stock split was 1:10 on 2024-06-17.
How did Perspective Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.23 | Growth: 44.71%.
Where can I find Perspective Therapeutics, Inc.'s investor relations reports?
Visit https://www.perspectivetherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Perspective Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Perspective Therapeutics, Inc. stock?
All-time high: $19.05 (2024-05-15) | All-time low: $1.60 (2025-04-09).
What are the key trends affecting Perspective Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Perspective Therapeutics, Inc. ( CATX ) UBS Global Healthcare Conference 2025 November 11, 2025 4:15 PM EST Company Participants Joel Sendek - Chief Financial Officer Annie Cheng - Vice President of Investor Relations Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Great. Thanks, everyone, for joining us.
globenewswire.com
SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:
globenewswire.com
SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 10, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
seekingalpha.com
Perspective Therapeutics, Inc. (NYSE:CATX ) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO October 20, 2025 8:30 AM EDT Company Participants Annie Cheng - Vice President of Investor Relations Johan Spoor - CEO & Director Markus Puhlmann - Chief Medical Officer Steve Keefe - Senior Vice President of Clinical Development Conference Call Participants Richard Wahl Leonid Timashev - RBC Capital Markets, Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Alec Stranahan - BofA Securities, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Phillip Eckert - LifeSci Capital, LLC, Research Division Justin Walsh - JonesTrading Institutional Services, LLC, Research Division David Nierengarten - Wedbush Securities Inc., Research Division Christopher Liu - Lucid Capital Markets, LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Jeet Mukherjee - BTIG, LLC, Research Division Presentation Operator Greetings.
globenewswire.com
SEATTLE, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended June 30, 2025.
seekingalpha.com
Perspective Therapeutics' pipeline, led by VMT-a-NET, shows promising safety and early efficacy, but lacks clear superiority over existing therapies like Lutathera so far. The company maintains a strong cash position, supporting operations into late 2026, but the market now values CATX closer to its liquidity. Key risks include unproven clinical advantage for alpha emitter therapies and ongoing challenges with manufacturing, delivery, and market adoption.
globenewswire.com
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting taking place June 21-24, 2025 in New Orleans, Louisiana.
globenewswire.com
SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2025.
zacks.com
Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
globenewswire.com
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
See all news
